Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Udine – page 24

437 clinical trials in Udine, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Udine at a glance
437
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

437 trials in Udine

Open in trial search

Acute lymphocytic leukaemia

Not recruiting

Study of inotuzumab ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Acute graft versus host disease in intestine

Not recruiting

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Maat Pharma

Lupus nephritis

Not recruiting

Study on the Effects of Ianalumab with Standard Therapy for Patients with Active Lupus Nephritis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Neoplasm

Not recruiting

Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Turning Point Therapeutics Inc.

Oesophageal squamous cell carcinoma

Not recruiting

Study of Atezolizumab and Tiragolumab for Patients with Unresectable Esophageal Squamous Cell Carcinoma After Chemoradiotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

T-cell type acute leukaemia

Not recruiting

Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Anthos Therapeutics Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study on Radium-223, Docetaxel, and Prednisone for Patients with Bone-Only Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Study on Metformin for Patients with Osteosarcoma and Ewing's Sarcoma at High Risk of Relapse

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Istituto Ortopedico Rizzoli

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Udine

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials investigating treatments for various cancer types, including leukemia, gastric cancer, and multiple myeloma. Studies focus on targeted therapies and immunotherapy approaches.

  • Chronic Myeloid Leukemia Treatment
  • Gastroesophageal Cancer Therapy
  • Advanced Pancreatic Cancer Management

Research emphasizes personalized treatment approaches and combination therapies to improve patient outcomes.

02 Autoimmune Conditions

Studies examining new therapeutic options for inflammatory and autoimmune disorders, with particular focus on psoriatic arthritis and Sjögren's Syndrome.

  • Biomarker Analysis in Psoriatic Arthritis
  • Novel Treatments for Inflammatory Conditions
  • Long-term Disease Management

Trials aim to evaluate both safety and efficacy of innovative biological treatments.

03 Cardiovascular Studies

Research focusing on heart health and prevention, including studies of heart failure prevention and treatment of recurrent pericarditis.

  • Heart Failure Prevention Strategies
  • Pericarditis Treatment Innovation
  • Cardiovascular Risk Management

Investigations center on both preventive approaches and therapeutic interventions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.